• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合建模可用于回答随机临床试验中的各种研究问题。

Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials.

机构信息

Department of Biomedical Data Science and Center for Innovative Study Design, School of Medicine, Stanford University, Stanford, CA, USA; Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Department of Health Evidence, Section Biostatistics, Radboud Medical Center Nijmegen, Nijmegen, The Netherlands.

出版信息

J Clin Epidemiol. 2022 Jul;147:32-39. doi: 10.1016/j.jclinepi.2022.03.009. Epub 2022 Mar 26.

DOI:10.1016/j.jclinepi.2022.03.009
PMID:35346783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10266556/
Abstract

OBJECTIVES

Correlated longitudinal and time-to-event outcomes, such as the rate of cognitive decline and the onset of Alzheimer's disease, are frequent (co-)primary and key secondary endpoints in randomized clinical trials (RCTs). Despite their biological associations, these types of data are often analyzed separately, leading to loss of information and increases in bias. In this paper, we set out how joint modeling of longitudinal and time-to-event endpoints can be used in RCTs to answer various research questions.

STUDY DESIGN AND SETTING

The key concepts of joint models are introduced and illustrated for a completed trial in amyotrophic lateral sclerosis.

RESULTS

The output of a joint model can be used to answer different clinically relevant research questions, where the interpretation of effect estimates and those obtained from conventional methods are similar. Albeit joint models have the potential to overcome the limitations of commonly used alternatives, they require additional assumptions regarding the distributions, as well as the associations between two endpoints.

CONCLUSION

Improving the uptake of joint models in RCTs may start by outlining the exact research question one seeks to answer, thereby determining how best to prespecify the model and defining the parameter that should be of primary interest.

摘要

目的

相关性纵向和事件时间结局,如认知能力下降的速度和阿尔茨海默病的发病,是随机临床试验(RCT)中常见的(共同)主要和关键次要终点。尽管这些数据具有生物学相关性,但通常会分开分析,导致信息丢失和偏倚增加。本文介绍了如何在 RCT 中联合建模纵向和事件时间终点,以回答各种研究问题。

研究设计和背景

介绍了联合模型的关键概念,并对肌萎缩侧索硬化症的已完成试验进行了说明。

结果

联合模型的输出可用于回答不同的临床相关研究问题,其效应估计值的解释与传统方法相似。尽管联合模型有可能克服常用替代方法的局限性,但它们需要对分布以及两个终点之间的关联做出额外的假设。

结论

通过概述希望回答的确切研究问题,可以提高 RCT 中联合模型的应用,从而确定如何最好地预先指定模型并定义主要关注的参数。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14a1/10266556/5de86b8bfa4a/nihms-1793876-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14a1/10266556/bfbdd2e22e64/nihms-1793876-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14a1/10266556/5de86b8bfa4a/nihms-1793876-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14a1/10266556/bfbdd2e22e64/nihms-1793876-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14a1/10266556/5de86b8bfa4a/nihms-1793876-f0002.jpg

相似文献

1
Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials.联合建模可用于回答随机临床试验中的各种研究问题。
J Clin Epidemiol. 2022 Jul;147:32-39. doi: 10.1016/j.jclinepi.2022.03.009. Epub 2022 Mar 26.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.肌萎缩侧索硬化症随机临床试验中的功能丧失和死亡率:要合并,还是不要合并——这就是估计目标。
Clin Pharmacol Ther. 2022 Apr;111(4):817-825. doi: 10.1002/cpt.2533. Epub 2022 Feb 17.
4
Joint latent class model: Simulation study of model properties and application to amyotrophic lateral sclerosis disease.联合潜在类别模型:模型性质的模拟研究及其在肌萎缩侧索硬化症中的应用。
BMC Med Res Methodol. 2021 Sep 30;21(1):198. doi: 10.1186/s12874-021-01377-9.
5
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
6
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2007 Jan 24(1):CD001447. doi: 10.1002/14651858.CD001447.pub2.
7
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206.
8
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).利鲁唑用于治疗肌萎缩侧索硬化症(ALS)/运动神经元病(MND)。
Cochrane Database Syst Rev. 2002(2):CD001447. doi: 10.1002/14651858.CD001447.
9
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.重组人胰岛素样生长因子I(rhIGF-I)用于治疗肌萎缩侧索硬化症/运动神经元病。
Cochrane Database Syst Rev. 2002(3):CD002064. doi: 10.1002/14651858.CD002064.
10
Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.重组人胰岛素样生长因子I(rhIGF-I)用于治疗肌萎缩侧索硬化症/运动神经元病。
Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD002064. doi: 10.1002/14651858.CD002064.pub3.

引用本文的文献

1
Handling rescue therapy in myasthenia gravis clinical trials: why it matters and why you should care.重症肌无力临床试验中的救援治疗处理:为何重要以及你为何应予以关注。
Ann Clin Transl Neurol. 2025 May;12(5):888-897. doi: 10.1002/acn3.52309. Epub 2025 Apr 16.
2
Predicting progression-free survival from measurable residual disease in chronic lymphocytic leukemia.预测慢性淋巴细胞白血病可测量残留病中的无进展生存期。
Clin Transl Sci. 2024 Aug;17(8):e13905. doi: 10.1111/cts.13905.
3
Association between urea trajectory and protein dose in critically ill adults: a secondary exploratory analysis of the effort protein trial (RE-EFFORT).

本文引用的文献

1
Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine-That is the Estimand.肌萎缩侧索硬化症随机临床试验中的功能丧失和死亡率:要合并,还是不要合并——这就是估计目标。
Clin Pharmacol Ther. 2022 Apr;111(4):817-825. doi: 10.1002/cpt.2533. Epub 2022 Feb 17.
2
Dynamic prediction models improved the risk classification of type 2 diabetes compared with classical static models.动态预测模型比传统静态模型更能改善 2 型糖尿病的风险分类。
J Clin Epidemiol. 2021 Dec;140:33-43. doi: 10.1016/j.jclinepi.2021.08.026. Epub 2021 Aug 27.
3
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order.
危重症成人尿素轨迹与蛋白剂量的关系:努力蛋白试验(RE-EFFORT)的二次探索性分析。
Crit Care. 2024 Jan 16;28(1):24. doi: 10.1186/s13054-024-04799-1.
4
Exploring flexible polynomial regression as a method to align routine clinical outcomes with daily data capture through remote technologies.探索灵活多项式回归,作为一种通过远程技术将常规临床结果与日常数据采集对齐的方法。
BMC Med Res Methodol. 2023 May 11;23(1):114. doi: 10.1186/s12874-023-01942-4.
创新肌萎缩侧索硬化症临床试验:挑战既定秩序。
Neurology. 2021 Sep 14;97(11):528-536. doi: 10.1212/WNL.0000000000012545. Epub 2021 Jul 27.
4
Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials.大多数肿瘤学随机对照试验中,由于生活质量数据缺失而导致的信息性删失评估不足。
J Clin Epidemiol. 2021 Nov;139:80-86. doi: 10.1016/j.jclinepi.2021.07.013. Epub 2021 Jul 24.
5
Bayesian design of clinical trials using joint models for longitudinal and time-to-event data.使用纵向和生存数据联合模型进行临床试验的贝叶斯设计。
Biostatistics. 2022 Apr 13;23(2):591-608. doi: 10.1093/biostatistics/kxaa044.
6
A marginal estimate for the overall treatment effect on a survival outcome within the joint modeling framework.联合建模框架内对生存结局的总体治疗效果的边际估计。
Stat Med. 2020 Dec 10;39(28):4120-4132. doi: 10.1002/sim.8713. Epub 2020 Aug 24.
7
MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a "de jure" estimand.基于“法定”评估目标,使用 MMRM 与纵向反应和研究药物停药时间的联合建模对临床试验进行比较。
Pharm Stat. 2020 Nov;19(6):909-927. doi: 10.1002/pst.2045. Epub 2020 Jul 28.
8
Rethinking the intention-to-treat principle: one size does not fit all.重新思考意向性分析原则:一刀切并不适用。
J Clin Epidemiol. 2020 Sep;125:198-200. doi: 10.1016/j.jclinepi.2020.04.023. Epub 2020 May 4.
9
Bayesian joint modelling of longitudinal and time to event data: a methodological review.纵向数据与事件发生时间数据的贝叶斯联合建模:方法学综述
BMC Med Res Methodol. 2020 Apr 26;20(1):94. doi: 10.1186/s12874-020-00976-2.
10
An introduction to joint models-applications in nephrology.联合模型介绍——在肾脏病学中的应用
Clin Kidney J. 2020 Apr 8;13(2):143-149. doi: 10.1093/ckj/sfaa024. eCollection 2020 Apr.